These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 32749940)

  • 1. Bortezomib, Melphalan, Dexamethasone: A New Standard of Care for AL Amyloidosis?
    Pratt G
    J Clin Oncol; 2020 Oct; 38(28):3243-3244. PubMed ID: 32749940
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy of bortezomib, cyclophosphamide and dexamethasone in cardiac AL amyloidosis.
    Brennan X; Withers B; Jabbour A; Milliken S; Kotlyar E; Fay K; Ma D; Muthiah K; Hamad N; Dodds A; Bart N; Keogh A; Hayward C; Macdonald P; Moore J
    Intern Med J; 2022 Oct; 52(10):1826-1830. PubMed ID: 36266066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment strategy for immunoglobulin light chain amyloidosis].
    Fuchida SI
    Rinsho Ketsueki; 2021; 62(8):1160-1166. PubMed ID: 34497203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Immunomodulatory drugs in the treatment of primary systemic light chain amyloidosis].
    Charliński G; Wiater E; Jedrzejczak WW
    Pol Merkur Lekarski; 2012 Apr; 32(190):217-20. PubMed ID: 22708276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach.
    Palladini G; Milani P; Foli A; Obici L; Lavatelli F; Nuvolone M; Caccialanza R; Perlini S; Merlini G
    Haematologica; 2014 Apr; 99(4):743-50. PubMed ID: 24213149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis.
    Kastritis E; Leleu X; Arnulf B; Zamagni E; Cibeira MT; Kwok F; Mollee P; Hájek R; Moreau P; Jaccard A; Schönland SO; Filshie R; Nicolas-Virelizier E; Augustson B; Mateos MV; Wechalekar A; Hachulla E; Milani P; Dimopoulos MA; Fermand JP; Foli A; Gavriatopoulou M; Klersy C; Palumbo A; Sonneveld P; Johnsen HE; Merlini G; Palladini G
    J Clin Oncol; 2020 Oct; 38(28):3252-3260. PubMed ID: 32730181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined use of bortezomib, cyclophosphamide, and dexamethasone induces favorable hematological and organ responses in Japanese patients with amyloid light-chain amyloidosis: a single-institution retrospective study.
    Kikukawa Y; Yuki H; Hirata S; Ide K; Nakata H; Miyakawa T; Matsuno N; Nosaka K; Yonemura Y; Kawaguchi T; Hata H; Mitsuya H; Okuno Y
    Int J Hematol; 2015 Feb; 101(2):133-9. PubMed ID: 25430082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bortezomib-dexamethasone versus high-dose melphalan for Japanese patients with systemic light-chain (AL) amyloidosis: a retrospective single-center study.
    Katoh N; Ueno A; Yoshida T; Tazawa KI; Shimojima Y; Gono T; Sekijima Y; Matsuda M; Ikeda SI
    Int J Hematol; 2017 Mar; 105(3):341-348. PubMed ID: 27832515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful treatment of renal light chain (AL) amyloidosis with bortezomib and dexamethasone (VD).
    Huang B; Li J; Xu X; Zheng D; Zhou Z; Liu J
    Pathol Biol (Paris); 2015 Feb; 63(1):17-20. PubMed ID: 25455933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclophosphamide + Thalidomide + Dexamethasone Versus Melphalan + Dexamethasone for the Treatment of Amyloid Light-chain Amyloidosis With Kidney Involvement: A Retrospective Study in Chinese Patients.
    Liu B; Wang Y; Bai M; Wang D; Zhao J; Zhang M; Sun S
    Clin Ther; 2019 Jun; 41(6):1186-1198. PubMed ID: 30718006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of systemic AL amyloidosis: about 25 cases].
    Eddou H; Zinebi A; Maaroufi HE; Moudden MK; Doghmi K; Mikdame M; Baaj ME
    Pan Afr Med J; 2017; 28():160. PubMed ID: 29541306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction Therapy with Bortezomib Followed by Bortezomib-High Dose Melphalan and Stem Cell Transplantation for Light Chain Amyloidosis: Results of a Prospective Clinical Trial.
    Sanchorawala V; Brauneis D; Shelton AC; Lo S; Sun F; Sloan JM; Quillen K; Seldin DC
    Biol Blood Marrow Transplant; 2015 Aug; 21(8):1445-51. PubMed ID: 25858810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential cyclophosphamide-bortezomib-dexamethasone unmasks the harmful cardiac effect of dexamethasone in primary light-chain cardiac amyloidosis.
    Le Bras F; Molinier-Frenkel V; Guellich A; Dupuis J; Belhadj K; Guendouz S; Ayad K; Colombat M; Benhaiem N; Tissot CM; Hulin A; Jaccard A; Damy T
    Eur J Cancer; 2017 May; 76():183-187. PubMed ID: 28334621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies.
    Kastritis E; Roussou M; Gavriatopoulou M; Migkou M; Kalapanida D; Pamboucas C; Kaldara E; Ntalianis A; Psimenou E; Toumanidis ST; Tasidou A; Terpos E; Dimopoulos MA
    Am J Hematol; 2015 Apr; 90(4):E60-5. PubMed ID: 25580702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on the Contemporary Treatment of Light Chain Amyloidosis Including Stem Cell Transplantation.
    Abdallah M; Sanchorawala V
    Am J Med; 2022 Apr; 135 Suppl 1():S30-S37. PubMed ID: 35081382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction Therapy with Bortezomib and Dexamethasone and Conditioning with High-Dose Melphalan and Bortezomib Followed by Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis: Long-Term Follow-Up Analysis.
    Gupta VK; Brauneis D; Shelton AC; Quillen K; Sarosiek S; Sloan JM; Sanchorawala V
    Biol Blood Marrow Transplant; 2019 May; 25(5):e169-e173. PubMed ID: 30639823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of the Presence of t(11;14) for Patients With AL Amyloidosis Treated With Bortezomib-Containing Regimens: Experience From the Amyloidosis Program of Calgary.
    Lewis E; McCulloch S; Mahe E; Bahlis N; Neri P; Tay J; Duggan P; Jimenez-Zepeda VH
    Clin Lymphoma Myeloma Leuk; 2023 Oct; 23(10):e331-e334. PubMed ID: 37532664
    [No Abstract]   [Full Text] [Related]  

  • 18. Induction bortezomib in Al amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective study.
    Scott EC; Heitner SB; Dibb W; Meyers G; Smith SD; Abar F; Kovacsovics T; Perez-Avraham G; Stentz A; Frires R; Dibb J; Maziarz RT
    Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):424-430.e1. PubMed ID: 24650974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens.
    Bochtler T; Hegenbart U; Kunz C; Granzow M; Benner A; Seckinger A; Kimmich C; Goldschmidt H; Ho AD; Hose D; Jauch A; Schönland SO
    J Clin Oncol; 2015 Apr; 33(12):1371-8. PubMed ID: 25779559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 1 study of bortezomib in combination with melphalan and dexamethasone in Japanese patients with relapsed AL amyloidosis.
    Shimazaki C; Fuchida S; Suzuki K; Ishida T; Imai H; Sawamura M; Takamatsu H; Abe M; Miyamoto T; Hata H; Yamada M; Ando Y
    Int J Hematol; 2016 Jan; 103(1):79-85. PubMed ID: 26588925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.